N/A
N=155
BARD® Study of LIFESTREAM™ Balloon Expandable Covered Stent Treating Iliac Arterial Occlusive Disease
Peripheral Artery Disease · Peripheral Vascular Disease · Arterial Occlusive Disease
Bottom Line
View on ClinicalTrials.gov: NCT02228564 ↗Enrolled (actual)
155
Serious AEs
38.7%
Results posted
Oct 2020
Primary outcome: Primary: Number of Participants With Device and/or Procedure-Related Death or Myocardial Infarction (MI) Through 30 Days, or Any Target Lesion Revascularization (TLR), Target Limb(s) Major Amputation, or Restenosis Through 9-Months Post Index Procedure. — 16 Participants — p=<0.0325
Study Design & Population
- Study type
- Interventional
- Phase
- N/A
- Interventions
- Percutaneous transluminal angioplasty (PTA) (Procedure); LIFESTREAM™ covered stent (Device)
- Age
- Adult, Older Adult · 21+ yrs
- Sex
- All
- Sponsor
- C. R. Bard
- Primary completion
- Dec 2016
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Number of Participants With Device and/or Procedure-Related Death or Myocardial Infarction (MI) Through 30 Days, or Any Target Lesion Revascularization (TLR), Target Limb(s) Major Amputation, or Restenosis Through 9-Months Post Index Procedure. |
16 | <0.0325 sig |
| SECONDARY Number of Participants With Major Adverse Events (MAEs) Through 9-Months Post Index Procedure. |
7 | — |
| SECONDARY Number of Lesions With Acute Lesion Success |
188 | — |
| SECONDARY Number of Participants With Acute Procedure Success |
148 | — |
| SECONDARY Number of Devices With Acute Technical Success at Index Procedure |
226 | — |
| SECONDARY Number of Participants With Target Lesion Revascularization (TLR) at 6, 9, 12, 24, and 36 Months Post Index Procedure |
3; 5; 7; 19; 23 | — |
| SECONDARY Number of Participants With Target Vessel Revascularization (TVR) Event at 6, 9, 12, 24, and 36 Months Post Index Procedure. |
3; 5; 7; 19; 23 | — |
| SECONDARY Number of Participants With Sustained Clinical Success at 30-Days and 9, 12, 24, and 36 Months Post Index Procedure |
133; 124; 124; 106; 98 | — |
| SECONDARY Number of Participants With Primary Patency at 9, 12, 24, and 36 Months Post Index Procedure |
118; 110; 92; 72 | — |
| SECONDARY Number of Participants With Assisted Primary Patency at 9, 12, 24, and 36 Months Post Index Procedure |
119; 112; 98; 78 | — |
| SECONDARY Number of Participants With Secondary Patency at 9, 12, 24, and 36 Months Post Index Procedure. |
121; 112; 100; 79 | — |
| SECONDARY Change in Walking Impairment Questionnaire (WIQ) Scores at 30 Days, 9, 12, 24, and 36-Months Post Index Procedure Compared to Baseline. |
31.45; 32.10; 32.81; 31.34; 32.52 | — |
Summary
Collect confirmatory evidence of the safety and effectiveness of the Balloon LIFESTREAM™ Stent Graft for the treatment of stenoses and occlusion in the iliac arteries.
Eligibility Criteria
CLINICAL INCLUSION CRITERIA:
- The subject provides written informed consent using an Informed Consent Form approved by the Ethics Committee/ Institutional Review Board for the site.
- Subject agrees to comply with the protocol-mandated follow-up procedures and visits.
- Subject is a male or non-pregnant female ≥ 21 years old with an expected lifespan sufficient to allow for completion of all study procedures.
- Subject has intermittent claudication (Rutherford Category 2-3) or ischemic rest pain (Rutherford Category 4).
- Subject is able and willing to comply with any required medication regimen.
ANGIOGRAPHIC INCLUSION CRITERIA:
- Subject has evidence of single, bilateral, or multiple de novo and/or restenotic (non-stented) lesion in the native common and/or external iliac artery that is ≥ 50% stenosed (including total occlusions).
- The target lesion can be successfully crossed with a guide wire and pre-dilated with an appropriately sized PTA balloon.
- The reference vessel diameter is between 4.5 mm -12.0 mm in diameter.
- The target lesion is ≤ 100 mm in combined length (per side).
- The subject has angiographic evidence of a patent (< 50% stenosis) profunda and/or superficial femoral artery (SFA) in the target limb.
CLINICAL EXCLUSION CRITERIA:
- The subject is unable or unwilling to provide written informed consent or to conform to the study protocol follow-up procedures and visits.
- The subject is or plans to become pregnant during the study.
- The subject is asymptomatic, has mild claudication or critical limb ischemia with tissue loss described as Rutherford Category 0, 1, 5 or 6.
- The subject has a vascular graft previously implanted in the native iliac vessel.
- The subject suffered a hemorrhagic stroke or transient ischemic attack (TIA) within 3 months prior to the index procedure.
- The subject has a known uncorrectable bleeding diathesis or active coagulopathy.
- The subject has a serum creatinine ≥ 2.5 mg/dl or is on dialysis.
- The subject has a known allergy or sensitivity to stainless steel (i.e., Nickel), ePTFE, or has intolerance to the antiplatelet, anticoagulant or thrombolytic medications required per the protocol.
- The subject has a known allergy or sensitivity to contrast media, which cannot be adequately pre-medicated.
- The subject had a prior vascular intervention within 30 days before or planned for within 30 days after the index procedure.
- The subject has another medical condition, which may cause him/her to be non-compliant with the protocol, confound the data interpretation, or is associated with a life expectancy insufficient to allow for the completion of study procedures and follow-up.
- The subject is currently participating in an investigational drug, biologic, or another device study.
ANGIOGRAPHIC EXCLUSION CRITERIA:
- The subject has extensive peripheral vascular disease, which in the opinion of the Investigator, would preclude safe insertion of an introducer sheath. The ipsilateral common femoral artery should be patent (< 50% stenosis).
- The target lesion requires treatment other than angioplasty to facilitate subject device delivery.
- The subject has severe calcification of the target lesion, preventing inflation of PTA balloon.
- The target lesion has been previously treated with a stent (bare or covered).
- The subject has angiographic evidence of acute thrombus at the target lesion.
- The target lesion involves the origin of the internal iliac artery such that successful treatment of the lesion would require the subject device to cross/occlude the side branch.
- The target lesion located in the distal external iliac artery such that successful treatment of the lesion would require the subject device to cross/occlude side branches or be exposed to compressive forces associated with the close proximity to the common femoral artery.
- The subject has an abdominal aortic aneurysm (AAA) contiguous to the iliac artery target lesion.
- The subject has a pre-existing target il
Data sourced from ClinicalTrials.gov (NCT02228564). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.